Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
Vaccine
; 39(20): 2731-2735, 2021 05 12.
Article
in English
| MEDLINE | ID: covidwho-1193499
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has significantly affected utilization of preventative health care, including vaccines. We aimed to assess HPV vaccination rates during the pandemic, and conduct a simulation model-based analysis to estimate the impact of current coverage and future pandemic recovery scenarios on disease outcomes. The model population included females and males of all ages in the US. The model compares pre-COVID vaccine uptake to 3 reduced coverage scenarios with varying recovery speed. Vaccine coverage was obtained from Truven Marketscan™. Substantially reduced coverage between March-August 2020 was observed compared to 2018-2019. The model predicted that 130,853 to 213,926 additional cases of genital warts; 22,503 to 48,157 cases of CIN1; 48,682 to 110,192 cases of CIN2/3; and 2,882 to 6,487 cases of cervical cancer will occur over the next 100 years, compared to status quo. Providers should plan efforts to recover HPV vaccination and minimize potential long-term consequences.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Uterine Cervical Neoplasms
/
Papillomavirus Infections
/
Alphapapillomavirus
/
Papillomavirus Vaccines
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
North America
Language:
English
Journal:
Vaccine
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS